ArticleProceedings of the National Academy of Sciences of the United States of America1993
Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade.Bone research · 2026Article
- Basic biology and roles of CEBPD in cardiovascular disease.Cell death discovery · 2025Review
- Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.Cancer cell · 2023Article
- Nonstructural Protein 1 of Variant PEDV Plays a Key Role in Escaping Replication Restriction by Complement C3.Journal of virology · 2022Article
- Hop2 interacts with the transcription factor CEBPα and suppresses adipocyte differentiation.The Journal of biological chemistry · 2021Article
- Exposure to dim light at night prior to conception attenuates offspring innate immune responses.PloS one · 2020Article
- Hop2 Interacts with ATF4 to Promote Osteoblast Differentiation.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Article
- CCAAT/enhancer binding protein delta (C/EBPδ) deficiency does not affect bleomycin-induced pulmonary fibrosis.Journal of clinical and translational research · 2018Article
- Article
- Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.International journal of molecular sciences · 2017Review
- IL-17A enhances IL-13 activity by enhancing IL-13-induced signal transducer and activator of transcription 6 activation.The Journal of allergy and clinical immunology · 2017Article
- Hepatocytes: a key cell type for innate immunity.Cellular & molecular immunology · 2016Review
- Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes.Oncotarget · 2016Article
- Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein δ.Kidney international · 2015Article
- An anti-inflammatory role for C/EBPδ in human brain pericytes.Scientific reports · 2015Article
- Iron-induced Local Complement Component 3 (C3) Up-regulation via Non-canonical Transforming Growth Factor (TGF)-β Signaling in the Retinal Pigment Epithelium.The Journal of biological chemistry · 2015Article
- CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor.Journal of neuroinflammation · 2015Article
- Biological roles of CCAAT/Enhancer-binding protein delta during inflammation.Journal of biomedical science · 2015Article
- CCAAT-enhancer binding protein-β expression and elevation in Alzheimer's disease and microglial cell cultures.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
C3, the third component of complement, is critical in the host immune response in that it is involved in both the classical and alternative pathways of complement activation. We have previously shown that a region (bp -127 to -70) within the C3 promoter is indispensable for conferring interleukin 1 (IL-1) responsiveness to this gene. A sequence comparison reveals two CCAAT/enhancer binding protein (C/EBP) consensus sequences, basic DNA binding region and leucine zippers 1 and 2 (bZIP1 and bZIP2), within this region. Site-directed mutagenesis of the more 3' C/EBP site (bZIP1) in the C3 promoter significantly reduced the basal level of expression and the IL-1 responsiveness of the reporter gene, whereas mutation in the second, more 5', C/EBP consensus sequence (bZIP2) had a minimal effect on basal expression and IL-1 inducibility. Electrophoretic-mobility-shift assays, with and without antibodies to the different C/EBP proteins that "supershift" protein-DNA complexes, demonstrated that proteins binding at the 3' C/EBP site formed several complexes. Antibodies to C/EBP alpha supershifted the majority of complexes formed with extracts from control cells. Antibodies directed against C/EBP delta supershifted the major IL-1-inducible complexes. Western immunoblot analyses showed that the level of C/EBP delta protein was increased dramatically in the nuclei of Hep 3B2 cells after 4 h of IL-1 treatment. When Hep 3B2 cells were cotransfected with a C/EBP delta expression vector and a construct with a C3 promoter and a reporter gene, C/EBP delta was able to trans-activate the C3 promoter in an IL-1-responsive manner. The data strongly suggest that C/EBP delta is the major protein responsible for regulating the acute-phase expression of the human C3 gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.